Search results
Showing 31 to 40 of 40 results for menopause: diagnosis and management
NICE has developed a medtech innovation briefing (MIB) on Proov Confirm for ovulation confirmation .
Adalimumab for treating moderate to severe hidradenitis suppurativa (TA392)
Evidence-based recommendations on adalimumab (Humira) for treating active moderate to severe hidradenitis suppurativa in adults whose disease has not responded to conventional systemic therapy.
CG115/1 | Is contingency management effective in reducing alcohol consumption in people who misuse alcohol
This International Women’s Day, we’re specifically focusing on the invaluable contributions of two of the women who help shape our guidance through their independent / voluntary committee roles. Hear from them, as they talk about their involvement with NICE and what #InspireInclusion means to them.
Evidence-based recommendations on raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women.
Evidence-based recommendations on raloxifene and teriparatide for preventing osteoporotic fragility fractures in postmenopausal women who have osteoporosis.
NICE draft updated guideline recommends more treatment choices for menopause symptoms
New evidence shows that cognitive behavioural therapy (CBT) can help reduce menopause symptoms including hot flushes and night sweats, depressive symptoms and problems sleeping NICE has said in its draft updated guideline on menopause published today (17 November 2023).
NICE has outlined what aspects of menopause care will be updated in upcoming guidance, including areas where more research is needed.
The long-term safety and efficacy is inadequate on two procedures NICE is calling for further evidence on
people at risk. Menopause Most women experience some symptoms with menopause. The depletion of oestrogen associated with...